Hiraiwa T, Ito M, Imagawa A, Takamatsu J, Kuma K, Miyauchi A, Hanafusa T
First Department of Medicine, Osaka Medical College, Takatsuki city, Japan.
J Endocrinol Invest. 2006 Apr;29(4):380-4. doi: 10.1007/BF03344113.
The close relationship between iodine intake and the effects of anti-thyroid drugs (ATD) for Graves' disease (GD) has been well established. However, it remains unknown whether restriction of dietary iodine improves the effect of ATD. This study aimed to clarify this issue in Japanese patients with GD who routinely ingest large amounts of dietary iodine. We performed a prospective clinical study in 81 patients with newly diagnosed GD who were divided into an iodine restricted group and a control group. Urinary iodine, thyroid hormones and TSH receptor antibody were measured during the first 8 weeks of ATD therapy. Urinary iodine concentrations in the iodine restricted group were significantly lower than in the control group (p=0.043). However, there were no significant differences in the decrease of thyroid hormones and TSH receptor antibody between the two groups. Restriction of dietary iodine does not ameliorate the effect of ATD therapy for GD in an area of excessive iodine intake.
碘摄入量与抗甲状腺药物(ATD)治疗格雷夫斯病(GD)效果之间的密切关系已得到充分证实。然而,饮食碘限制是否能改善ATD的疗效仍不清楚。本研究旨在阐明这一问题,研究对象为日常摄入大量饮食碘的日本GD患者。我们对81例新诊断的GD患者进行了一项前瞻性临床研究,将其分为碘限制组和对照组。在ATD治疗的前8周内测量尿碘、甲状腺激素和促甲状腺激素受体抗体。碘限制组的尿碘浓度显著低于对照组(p=0.043)。然而,两组之间甲状腺激素和促甲状腺激素受体抗体的下降幅度没有显著差异。在碘摄入过量地区,饮食碘限制并不能改善ATD治疗GD的效果。